Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Controlled Release

• Publication date

  2010-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jconrel.2010.03.015PMID 20346382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modes of resistance to anti-angiogenic therapy

  2008cited by this paper
• ASA404: update on drug development.

  2008cited by this paper
• Multimodality Molecular Imaging of Tumor Angiogenesis

  2008cited by this paper
• Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide–paclitaxel conjugate in mice with breast cancer

  2008cited by this paper
• Targeted delivery of therapeutics to endothelium

  2008cited by this paper
• Tumor angiogenesis.

  2008cited by this paper
• Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.

  2008cited by this paper
• Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis

  2008cited by this paper
• ASA404: update on drug development

  2008cited by this paper
• Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.

  2008cited by this paper
• Enhanced Antitumor Efficacy of Clinical-Grade Vasculature-Targeted Liposomal Doxorubicin

  2008cited by this paper
• Ligand-targeted liposomal therapies of neuroblastoma.

  2007cited by this paper
• Drug resistance and the solid tumor microenvironment.

  2007cited by this paper
• Tumor’host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds

  2007cited by this paper
• Current development status of small-molecule vascular disrupting agents.

  2006cited by this paper
• Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors

  2006cited by this paper
• Immunogenic and structural properties of the Asn-Gly-Arg (NGR) tumor neovasculature-homing motif.

  2006cited by this paper
• Angiogenesis in Cancer

  2006cited by this paper
• Synchronous selection of homing peptides for multiple tissues by in vivo phage display

  2006cited by this paper
• Display technologies: Application for the discovery of drug and gene delivery agents

  2006cited by this paper
• Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

  2006cited by this paper
• Synergistic antitumor response of interleukin 2 with melphalan in isolated limb perfusion in soft tissue sarcoma-bearing rats.

  2005cited by this paper
• A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

  2005cited by this paper
• Vascular disrupting agents: a new class of drug in cancer therapy.

  2005cited by this paper
• Drug Delivery Systems: Entering the Mainstream

  2004cited by this paper
• Vascular Targeting Agents as Cancer Therapeutics

  2004cited by this paper
• Synergistic antitumor activity of histamine plus melphalan in isolated limb perfusion: preclinical studies.

  2004cited by this paper
• In vitro targeted killing of human endothelial cells by co-incubation of human serum and NGR peptide conjugated human albumin protein bearing alpha (1-3) galactose epitopes.

  2004cited by this paper
• Vascular‐targeting therapies for treatment of malignant disease

  2004cited by this paper
• Aminopeptidase A is a functional target in angiogenic blood vessels.

  2004cited by this paper
• Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.

  2003cited by this paper
• Molecular regulation of vessel maturation

  2003cited by this paper
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.

  2003cited by this paper
• Neuroblastoma: biological insights into a clinical enigma

  2003cited by this paper
• Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells.

  2003cited by this paper
• Mapping tumor vascular diversity by screening phage display libraries.

  2003cited by this paper
• Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

  2003cited by this paper
• Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs.

  2002cited by this paper
• Ligand-targeted therapeutics in anticancer therapy

  2002cited by this paper
• Structure-Activity Relationships of Linear and Cyclic Peptides Containing the NGR Tumor-homing Motif*

  2002cited by this paper
• Tumor Regression by Targeted Gene Delivery to the Neovasculature

  2002cited by this paper
• Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer.

  2001cited by this paper
• TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects

  2000cited by this paper
• Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

  2000cited by this paper
• Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13)

  2000cited by this paper
• Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.

  1998cited by this paper
• Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

  1997cited by this paper
• AMINOPEPTIDASE A IS A CONSTITUENT OF ACTIVATED PERICYTES IN ANGIOGENESIS

  1996influential reference
• Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation.

  1995cited by this paper
• Angiogenesis in cancer, vascular, rheumatoid and other disease

  1995cited by this paper

• Empowering Healthcare with Phage Display Technology.

  2025cites this paper
• Tumor Anti-angiogenesis: Nano-Arsenal will Kill the Crab

  2023cites this paper
• Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors

  2021cites this paper
• The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors

  2021cites this paper
• Remodeling tumor microenvironment with nanomedicines.

  2021cites this paper
• Natural and Synthetic Biopolymers in Drug Delivery and Tissue Engineering

  2021cites this paper
• The Complex and Integral Roles of Pericytes Within the Neurovascular Unit in Health and Disease

  2021cites this paper
• Phage Display for Imaging Agent Development

  2021cites this paper
• Nanoparticles Dual Targeting Both Myeloma Cells and Cancer-Associated Fibroblasts Simultaneously to Improve Multiple Myeloma Treatment

  2021influential citation
• Novel Treatments and Technologies Applied to the Cure of Neuroblastoma

  2021cites this paper
• Utilization of Lipid-Based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.

  2020cites this paper
• Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment

  2020cites this paper
• Jet‐Lagged Nanoparticles Enhanced Immunotherapy Efficiency through Synergistic Reconstruction of Tumor Microenvironment and Normalized Tumor Vasculature

  2020cites this paper
• Nano-therapeutics for modulating the tumour microenvironment: Design, development, and clinical translation.

  2020cites this paper
• Pericytes and Neurovascular Function in the Healthy and Diseased Brain

  2019cites this paper
• Targeting Angiogenesis in Neuroblastoma

  2019cites this paper
• Overcoming Biological Barriers in Neuroblastoma Therapy: The Vascular Targeting Approach with Liposomal Drug Nanocarriers.

  2019cites this paper
• Applications of Nanotechnology in the Diagnosis and Therapy of Stroke

  2019cites this paper
• Animal Tumor Models

  2018cites this paper
• Targeted nanomedicines for applications in preclinical cancer models

  2018cites this paper
• Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency.

  2018cites this paper
• In Vivo Translation of Peptide-Targeted Drug Delivery Systems Discovered by Phage Display.

  2018cites this paper
• Cancer stem cells‐emanated therapy resistance: Implications for liposomal drug delivery systems

  2018cites this paper
• Combination antitumor therapy with targeted dual‐nanomedicines☆

  2017cites this paper
• Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain

  2017cites this paper
• Molecular galactose–galectin association in neuroblastoma cells: An unconventional tool for qualitative/quantitative screening

  2017cites this paper
• Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.

  2017cites this paper
• How to Overcome Biologic Barriers for the Therapy of Neuroblastoma : The Tumor Vascular Targeted Approach

  2017cites this paper
• Ligand-targeted theranostic nanomedicines against cancer.

  2016cites this paper
• A new fluorescence-based optical imaging method to non-invasively monitor hepatic myofibroblasts in vivo

  2016cites this paper
• Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses.

  2016cites this paper
• Pericyte-targeting drug delivery and tissue engineering

  2016cites this paper
• Multi-functional vesicles for cancer therapy: The ultimate magic bullet.

  2016cites this paper
• New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK

  2015influential citation
• Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma

  2015cites this paper
• Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.

  2015cites this paper
• Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.

  2015cites this paper
• Aspartate-modified doxorubicin on its N-terminal increases drug accumulation in LAT1-overexpressing tumors

  2015cites this paper
• Functional liposomes in the cancer-targeted drug delivery

  2015cites this paper
• The Targeted-liposome Delivery System of Antitumor Drugs.

  2015cites this paper
• Targeted intracellular delivery of synergistic drug combinations: tackling drug resistance in human breast cancer

  2015influential citation
• Advances in an active and passive targeting to tumor and adipose tissues

  2015cites this paper
• Targeted Thermosensitive Liposomes and Mild Hyperthermia for Local Drug Delivery to Tumors

  2015cites this paper
• Isolation And Studying of Specificity of Bacteriophages Binding To Murine Lung Adenocarcinoma

  2015cites this paper
• Cytotoxic Effects of PEGylated Anti-EGFR Immunoliposomes Combined with Doxorubicin and Rhenium-188 Against Cancer Cells.

  2015cites this paper
• FullLengthResearch Article THE POTENTIAL ABILITY OF LIPOSOME TO TREAT CANCER DISEASE

  2014cites this paper
• Targeted thermosensitive liposomes: an attractive novel approach for increased drug delivery to solid tumors

  2014cites this paper
• Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies

  2014cites this paper
• Brain tumor-targeted drug delivery strategies

  2014cites this paper
• License for destruction: tumor-specific cytokine targeting.

  2014cites this paper
• Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.

  2014cites this paper
• sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.

  2014cites this paper
• Vascular-homing peptides for targeted drug delivery and molecular imaging: meeting the clinical challenges.

  2014cites this paper
• Anti-GD2 Etoposide-Loaded Immunoliposomes for the Treatment of GD2 Positive Tumors

  2014cites this paper
• Bridging cancer biology and the patients' needs with nanotechnology-based approaches.

  2014cites this paper
• Recent Advances with Liposomes as Drug Carriers

  2014cites this paper
• Ways to improve tumor uptake and penetration of drugs into solid tumors

  2014influential citation
• Desenvolvimento de lipossomas vetorizados ao receptor folato contendo paclitaxel e imatinibe coencapsulados: avaliação da atividade antiproliferativa e da expressão gênica do VEGF em células tumorais

  2014cites this paper
• Nanocarrier-Mediated Targeting of Tumor and Tumor Vascular Cells Improves Uptake and Penetration of Drugs into Neuroblastoma

  2013cites this paper
• From phage display to nanoparticle delivery: functionalizing liposomes with multivalent peptides improves targeting to a cancer biomarker.

  2013cites this paper
• Nanopreparations to overcome multidrug resistance in cancer.

  2013cites this paper
• Nanosized Vectors for Transfection Assembled from Peptides and Nucleic Acids

  2013cites this paper
• Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

  2013influential citation
• Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma

  2013cites this paper
• In vivo phage display--a discovery tool in molecular biomedicine.

  2013cites this paper
• Liposomal drug delivery systems: from concept to clinical applications.

  2013cites this paper
• Novel phage display-derived neuroblastoma-targeting peptides potentiate the effect of drug nanocarriers in preclinical settings.

  2013cites this paper
• Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.

  2013cites this paper
• Anti-angiogenesis in neuroblastoma.

  2013cites this paper
• The Different Faces of Angiogenesis in Neuroblastoma

  2012influential citation
• Peptide Targeted Lipid Nanoparticles for Anticancer Drug Delivery

  2012cites this paper
• The Effect of Poly(d,l-Lactide-co-Glycolide)-Alendronate Conjugate Nanoparticles on Human Osteoclast Precursors

  2012cites this paper
• Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin.

  2012cites this paper
• 11 The Different Faces of Angiogenesis in Neuroblastoma

  2012cites this paper
• The role of pericytes in angiogenesis.

  2011cites this paper
• Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity

  2011cites this paper
• APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes.

  2011cites this paper
• The use of the orthotopic model to validate antivascular therapies for cancer.

  2011cites this paper
• Decellularized Matrix from Tumorigenic Human Mesenchymal Stem Cells Promotes Neovascularization with Galectin-1 Dependent Endothelial Interaction

  2011cites this paper
• Tumor angiogenesis: molecular pathways and therapeutic targets

  2011cites this paper
• Mass Transport via Cellular Barriers and Endocytosis

  2011cites this paper
• A comparison of peptide and folate receptor targeting of cancer cells: from single agent to nanoparticle

  2011cites this paper
• Nanoparticle delivery strategies to target doxorubicin to tumor cells and reduce side effects.

  2010cites this paper
• Liposomes targeting tumour stromal cells

  2010cites this paper
• Development and Evaluation of Paclitaxel-Loaded Liposomal Formulations for Targeted Drug Delivery to Breast Cancer

  2010cites this paper
• NSHM Journal of Pharmacy and Healthcare Management

  year unknowncites this paper